Skip to main content

Arguments Over GDD Lawsuit Centralization on September 27

Arguments Over GDD Lawsuit Centralization on September 27

Arguments Over GDD Lawsuit Centralization on September 27

Introduction

The U.S. Judicial Panel on Multidistrict Litigation (JPML)  will consider oral arguments on whether to consolidate all Gadolinium Deposition Disease (GDD) lawsuits filed against the manufacturers of MRI contrast dyes for coordinated pretrial proceedings.

In a motion filed in July, plaintiffs' lawyers requested all gadolinium complaints pending in the federal court system be centralized in the Northern District of California. Each of the MRI contrast dye manufacturers has filed a response opposing the centralization process citing that there are too few plaintiffs’ law firms involved in the cases and too many different manufacturers to form a multidistrict litigation (MDL). Bayer Healthcare filed a supplemental response on September 20 in support of the motion and outlining arguments to be made during the upcoming hearing. The U.S. JPML  is set to hear oral arguments on the motions from several plaintiffs and manufacturers on September 27, at the Phillip Burton U.S. Courthouse in San Francisco.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.